BLASUBCUTANEOUSINJECTABLE
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
STARJEMZA (ustekinumab-hmny) by Bio-Thera Solutions is interleukin-12 antagonists [moa]. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STARJEMZA is a monoclonal antibody antagonist of interleukin-12 (IL-12) approved by the FDA on May 22, 2025. This is a biosimilar or novel formulation of ustekinumab designed for subcutaneous injection. The drug modulates immune responses by blocking IL-12 signaling, a key pathway in inflammatory and autoimmune diseases.
Launch
Early-stage launch product from emerging biotech sponsor with moderate competitive intensity; team building and market penetration roles likely expanding.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STARJEMZA is a newly launched biologic product in a competitive therapeutic area, offering entry-level to mid-career opportunities in brand commercialization, market access, and field-based roles. Career growth will depend on the product's ability to capture market share against entrenched competitors and the sponsor's commitment to pipeline investment.
Brand Manager
Worked on STARJEMZA at Bio-Thera Solutions? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.